This inventor holds 1 USPTO granted patent. Top assignee: Genzyme Corporation. Active years: 2006.
Company Filing History:
Years Active: 2006
Title: Kevin C Skinner: Innovator in Controlled Release of Anti-Arrhythmic Agents
Introduction
Kevin C Skinner is a notable inventor based in Andover, MA (US). He has made significant contributions to the field of medical technology, particularly in the development of methods for the controlled release of anti-arrhythmic agents. His innovative approach aims to enhance the effectiveness of cardiac treatments.
Latest Patents
Kevin C Skinner holds a patent for the "Controlled release of anti-arrhythmic agents." This patent describes methods for the simple and reliable application of selected anti-arrhythmia drugs from a hydrogel. The hydrogel can be applied to or polymerized on the tissues of the heart or its vessels, especially during cardiac bypass or other cardiac surgeries. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the target tissues. This innovative method allows for the effective delivery of drugs, such as amiodarone, which is known to lengthen the atrial effective refractory period.
Career Highlights
Kevin C Skinner is associated with Genzyme Corporation, where he has been able to apply his expertise in medical innovations. His work has contributed to advancements in cardiac care and has the potential to improve patient outcomes significantly.
Collaborations
Throughout his career, Kevin has collaborated with notable colleagues, including Robert J Miller and C Michael Philbrook. These collaborations have likely enriched his research and development efforts in the field of anti-arrhythmic treatments.
Conclusion
Kevin C Skinner's contributions to the field of medical technology, particularly in the controlled release of anti-arrhythmic agents, highlight his innovative spirit and dedication to improving cardiac care. His work continues to pave the way for advancements in medical treatments.